etoposide has been researched along with Small Cell Lung Carcinoma in 405 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (9.14) | 29.6817 |
| 2010's | 251 (61.98) | 24.3611 |
| 2020's | 117 (28.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, SM; Chen, TL; Christian, W; Detroja, D; Hwang, MJ; Lee, TC; Lin, YW; Pidugu, HB; Shah, A; Su, TL; Suen, CS; Wu, MH | 1 |
| Bai, X; Chen, H; De Brabander, JK; Kim, J; Liou, J; McFadden, DG; Posner, B; Povedano, JM; Rallabandi, R; Rice, L; Xie, Y; Ye, X | 1 |
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G | 1 |
| Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W | 1 |
| Cao, M; Ding, W; Guo, L; Luo, P; Lyu, Q; Wang, Q; Wei, T; Zhang, J; Zhu, W | 1 |
| Ahn, BC; Cho, BC; Hong, MH; Kim, HR; Lee, S; Lim, SM; Shim, HS | 1 |
| Economidou, SC; Fotopoulos, G; Vrontis, K | 1 |
| Antonini Cappellini, GC; Bria, E; Cappuzzo, F; Carpano, S; Carta, A; D'Argento, E; Fadda, GM; Gelibter, AJ; Giusti, R; Martelli, O; Metro, G; Minuti, G; Nelli, F; Ricciardi, S; Russano, M; Stefani, A | 1 |
| Al-Salama, ZT | 1 |
| Cheng, H; Kim, SY; Monteiro de Oliveira Novaes, J; Tariq, S | 1 |
| Li, J; Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Blackhall, F; Bratt, S; Brown, S; Chaturvedi, A; Descamps, T; Dive, C; Frese, KK; Galvin, M; Greenhalgh, M; Hossain, ASMM; Humphrey, S; Kerr, A; Lallo, A; Pearce, SP; Pearsall, S; Priest, L; Revill, M; Schenk, MW; Zhou, C | 1 |
| Li, L; Liu, J; Luo, F; Qu, Z; Zhou, Q; Zhu, L | 1 |
| Hu, Z; Huang, L; Jiang, S; Jin, P; Wang, J; Zhen, H | 1 |
| Dayen, C; Debieuvre, D; Dixmier, A; Falchero, L; Gally, S; Greenwood, W; Pau, D; Sibley-Revelat, A | 1 |
| Chu, J; Fang, J; Jin, N; Li, S; Li, T; Li, X; Li, Y; Liu, X; Sun, L; Xiu, Z; Zhu, G; Zhu, Y | 1 |
| Andrini, E; Ardizzoni, A; Artioli, F; Barbieri, F; Bonetti, A; Brighenti, M; Cinieri, S; Colantonio, I; Ficorella, C; Follador, A; Frassoldati, A; Gelsomino, F; Genova, C; Lamberti, G; Mazzoni, F; Pasello, G; Riccardi, F; Rihawi, K; Tiseo, M; Tognetto, M | 1 |
| Brustugun, OT; Engleson, J; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Hornslien, K; Killingberg, KT; Langer, SW; Madebo, T; Nyman, J; Risum, S; Schytte, T; Tsakonas, G | 1 |
| Barrows, ED; Blackburn, MJ; Liu, SV | 1 |
| Kim, JO; Kim, KH; Park, JY; Park, SG; Seo, MD | 1 |
| Bondarenko, I; Chen, Y; Conev, N; Dalvi, TB; Garassino, MC; Goldman, JW; Havel, L; Hochmair, MJ; Hotta, K; Ji, JH; Jiang, H; Losonczy, G; Mann, H; Musso, E; Özgüroğlu, M; Paz-Ares, L; Poltoratskiy, A; Reinmuth, N; Statsenko, G; Trukhin, D; Voitko, O | 1 |
| Hu, Z; Liao, J; Liu, C; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, Y; Zhao, X | 1 |
| Choi, E; Heo, MH; Kim, H; Kim, JY; Park, KU | 1 |
| An, J; Cao, L; Chen, C; Deng, P; Gu, Q; He, B; Hu, C; Jiang, J; Li, M; Qin, L; Yang, H | 1 |
| Cao, L; Chen, G; Cheng, Y; Fan, Y; Fang, Y; Gong, Y; He, Z; Hu, C; Jiang, L; Li, X; Liu, Q; Liu, Y; Lu, K; Min, X; Shi, W; Wang, J; Wang, Q; Wu, J; Xu, F; Xu, X; Yang, R; Yao, W; Yao, Y; Yu, G; Zhang, B; Zhang, X; Zhao, J; Zhao, W; Zhou, C | 1 |
| Kuai, X; Liu, K; Liu, S; Tao, Z; Wang, G; Xia, S; Zhang, H; Zhu, H | 1 |
| Byers, L; Califano, R; Chafin, W; Cho, BC; Faivre-Finn, C; Jabbour, SK; Kato, T; Lai, WV; Rimner, A; Rudin, CM; Yu, J; Yu, L; Zhao, B | 1 |
| Imai, H; Kagamu, H; Kaira, K; Kishikawa, T; Minato, K; Minemura, H; Mouri, A; Nagai, Y; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y; Yamaguchi, O | 1 |
| Fukuizumi, A; Gemma, A; Hirao, M; Matsuda, K; Miyanaga, A; Noro, R; Omori, M; Seike, M; Takano, N | 1 |
| Imai, H; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Minato, K; Minemura, H; Mouri, A; Nagai, Y; Shiihara, J; Shiono, A; Taniguchi, H; Tsuda, T; Wasamoto, S; Yamada, Y; Yamaguchi, O | 1 |
| Bischoff, H; Cardona, A; De Boer, R; de Castro Junior, G; Dziadziuszko, R; Garassino, MC; Hochmair, M; Krzakowski, M; Lam, S; Liu, SV; Losonczy, G; Mansfield, A; Mok, TSK; Morris, S; Reck, M; Smolin, A; Sugawara, S | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Chen, Q; Huang, J; Lin, L; Lv, D; Pan, W; Wu, G; Wu, X; Yan, S | 1 |
| Chmielewska, I; Grodkiewicz, M; Korbel, MA; Koziel, P; Milanowski, J | 1 |
| Arnold, HU; Friesen, TJ; Garrison, SM; Hiatt, JB; Houghton, AM; Liao, SY; MacPherson, D; Martins, R; Norton, JP; Rienhoff, HY; Sandborg, H; Srivastava, S; Sutherland, KD; Wu, F | 1 |
| Dębczyński, M; Kuklińska, B; Mojsak, D; Mróz, RM | 1 |
| Imai, H; Kaburagi, T; Kagamu, H; Kaira, K; Kanazawa, K; Kishikawa, T; Masubuchi, K; Minato, K; Minemura, H; Nagai, Y; Shiihara, J; Shiono, A; Takechi, H; Taniguchi, H; Tsuda, T; Umeda, Y; Wasamoto, S; Yamada, Y | 1 |
| Chen, L; Chen, Y; Deng, P; Dong, Y; Han, B; Kong, T; Liu, D; Qian, F; Yang, H; Zhang, B; Zhang, W; Zhang, Y | 1 |
| Arkania, E; Bai, Y; Chen, J; Cheng, Y; Dvorkin, M; Han, L; Ji, Y; Kang, W; Li, X; Makharadze, T; Melkadze, T; Min, X; Pan, Y; Pan, Z; Shi, J; Sun, H; Viguro, M; Wang, Q; Wang, X; Wen, G; Wu, L; Yang, J; Zhao, Y; Zhu, J | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, JW; Huang, YH; Tseng, JS; Wu, JJ; Yang, TY | 1 |
| Alkassis, S; Austin, A; Azar, I; Chi, J; Chopra, A; Jang, H; Kim, S; Mamdani, H; Mehdi, S; Neu, K; Saha, BK; Yazdanpanah, O | 1 |
| Kang, HS; Kim, JW; Kim, SJ; Kim, SK; Lee, SH; Lim, JU; Shin, AY; Yeo, CD | 1 |
| Asao, T; Kobayashi, K; Morita, S; Tanaka, T; Watanabe, S | 1 |
| Azuma, K; Ishii, H; Kawashima, Y; Kurata, T; Okamoto, I; Okamoto, M; Shimose, T; Shingu, N; Yoshioka, H | 1 |
| Liu, K; Qin, Q; Zhu, H; Zhu, Y | 1 |
| Gon, Y; Iida, Y; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Murakami, H; Naito, T; Ono, A; Shimizu, T; Takahashi, T; Wakuda, K | 1 |
| Chen, X; Geng, Y; Hu, Y; Jiang, W; Li, Q; Lu, B; Luo, D; Ma, Z; Ouyang, W; Su, S; Wang, M; Wu, B; Yang, W | 1 |
| Huang, Z; Zhang, Y | 1 |
| Ozyilkan, O; Sedef, AK; Sumbul, AT; Yildirim, BA | 1 |
| Eom, JS; Jo, EJ; Kim, KU; Kim, MH; Kim, SH; Lee, K; Lee, MK; Mok, J; Park, HK | 1 |
| Gunarić, A; Karan Križanac, D; Kraljević, M; Šekerija Zovko, S; Tomić, K | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Hirata, J; Jimbo, N; Nakano, Y; Okamura, Y; Terakawa, T; Ueki, H | 1 |
| He, Z; Jiang, N; Su, B; Xu, B; Xu, T; Yu, X; Zhang, Y; Zhou, J; Zhu, Y | 1 |
| Che, G; Chen, Y; Gou, H; Huang, Q; Jiang, L; Liao, H; Lu, Y; Zhang, Y; Zhou, N | 1 |
| Kang, K; Lin, G; Lu, Y; Luo, R; Wang, H; Yao, Z | 1 |
| Kimura, T; Kurita, T; Miyoshi, AI; Ueda, Y; Yoshino, K | 1 |
| Chen, M; Han, H; Lin, X; Lv, T; Qiu, G; Song, Y; Xie, J; Xu, K; Ye, J; Zhan, P | 1 |
| Deng, W; Dong, X; Jiang, L; Li, L; Liao, A; Min, Y; Shi, A; Yang, D; Yu, H; Yu, R; Zhao, J | 1 |
| Goto, Y; Hamamoto, R; Horinouchi, H; Imabayashi, T; Kohno, T; Masuda, K; Matsumoto, Y; Motoi, N; Nakagawa, K; Ohe, Y; Okuma, Y; Shinno, Y; Shiraishi, K; Shirasawa, M; Takayanagi, D; Takigami, A; Tsuchida, T; Watanabe, SI; Yamamoto, N; Yoshida, T; Yoshida, Y; Yotsukura, M | 1 |
| Alamgeer, M; Cain, JE; Chen, J; DeVeer, M; Ganju, V; Garama, DJ; Gough, DJ; Guanizo, AC; Inampudi, C; Jakasekara, WSN; Luong, Q; Thakur, N; Watkins, DN | 1 |
| Chihara, Y; Date, K; Harada, T; Ishida, M; Iwasaku, M; Kanda, H; Kim, YH; Morimoto, K; Shiotsu, S; Takayama, K; Takeda, T; Takemura, Y; Tamiya, N; Tokuda, S; Yamada, T; Yoshimura, A | 1 |
| Artaç, M; Bozcuk, H; Eser, İ; Mutlu, H | 1 |
| Fu, C; Lin, GH; Wang, BC | 1 |
| Agarwal, M; Almquist, D; Ernani, V; Langlais, BT; Leventakos, K; Liu, A; Manochakian, R; Yu, NY | 2 |
| Honda, H; Kitamura, Y; Kudo, S; Morikawa, K; Sawai, T; Suzuki, K; Yamada, G; Yokoo, K | 1 |
| Li, Y; Wang, T; Zheng, X | 1 |
| Arriola, E; Cruz-Castellanos, P; Dómine, M; García-Campelo, R; Insa, A; Juan Vidal, O; Morán, T; Reguart, N; Sullivan, I; Zugazagoitia, J | 1 |
| Bullock, TN; Carducci, MA; Gentzler, RD; Hanley, M; Horton, B; Kim, K; Mock, J; Park, KS; Phelps, MA; Piekarz, R; Rhee, JC; Rudek, MA; Rudin, CM; Villaruz, LC | 1 |
| Akagi, K; Dotsu, Y; Fukuda, M; Gyotoku, H; Hayashi, F; Hisamatsu, Y; Ikeda, T; Kinoshita, A; Morinaga, R; Mukae, H; Nagashima, S; Nakatomi, K; Ogata, R; Ono, S; Senju, H; Shimada, M; Soda, H; Sugasaki, N; Tagawa, R; Takemoto, S; Taniguchi, H; Tomono, H; Umeyama, Y | 1 |
| Chen, Y; Feng, J; Guo, R; Han, Z; Jiang, F; Pan, B; Shen, B; Shi, L; Song, H; Wang, L; Wang, Q; Wu, Y; Yang, K; Zhao, W; Zhou, G; Zhou, T; Zhou, W; Zhou, X | 1 |
| Hara, Y; Hashimoto, H; Horita, N; Kaneko, A; Kaneko, T; Kobayashi, N; Kubo, S; Kudo, M; Matsumoto, H; Somekawa, K; Teranishi, S; Watanabe, K | 1 |
| Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K | 1 |
| Dai, G; Gao, M; Hu, J; Li, L; Ma, J; Wang, Y; Yan, H; Yang, X; Zhang, X; Zhao, Y | 1 |
| Li, K; Lin, A; Lin, W; Luo, P; Qiu, Z; Wang, Q; Wei, T; Zhang, J; Zhu, W | 1 |
| Cheng, PN; Ho, JC; Lam, SK; Xu, S | 1 |
| Capoccetti, F; Castagnoli, H; Fattori, S; Manni, C; Marchesani, F; Rossi, G | 1 |
| Guo, L; Guo, Y; Huang, W; Li, M; Liang, S; Peng, J; Wang, Q; Wang, S; Zeng, F; Zhu, W | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Abrouk, N; Brown, B; Burbano, E; Caroen, S; Carter, CA; Coyle, A; Ferry, L; Larson, C; Oronsky, A; Oronsky, B; Quinn, M; Reid, TR; Scribner, CL; Thilagar, B; Varner, G | 1 |
| Escriu, C; Sallam, M; Wong, H | 1 |
| Bao, Y; Chen, M; Chen, MY; Chen, PC; Chen, QX; Dong, BQ; Fan, Y; Fang, M; Guo, Y; Hong, W; Hu, X; Jiang, YH; Jin, Y; Kong, Y; Liu, JS; Ma, HL; Mao, WM; Peng, F; Song, ZB; Sun, WY; Tang, HR; Wang, J; Xu, XL; Xu, YJ; Yu, C; Yu, XM; Zhang, L; Zhang, YP; Zhao, Q; Zhou, XM; Zhu, HN; Zhu, L | 1 |
| Baker, J; Dexter, PR; He, J; Hui, SL; Jin, F; Kachroo, S; Shao, C; Zhang, Z | 1 |
| De Petris, L; Fang, F; Lewensohn, R; Pettersson, A; Tendler, S; Viktorsson, K; Zhan, Y | 1 |
| Bai, H; Duan, J; Guo, R; Li, J; Sun, J; Wang, J; Wang, Z | 1 |
| Armstrong, SA; Liu, SV | 1 |
| Aquin, T; Banerji, S; Bucher, O; Dawe, DE; Green, S; Rittberg, R | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Balakrishnan, A; Kumar, P; Prasanna, BK | 1 |
| Awad, MM; Cheema, PK; Csőszi, T; Ebiana, V; Gottfried, M; Gümüş, M; Kalemkerian, GP; Kato, T; Kim, HR; Luft, A; Luo, Y; Mazieres, J; Navarro, A; Orlandi, FJ; Peters, S; Pietanza, MC; Rodriguez-Abreu, D; Rudin, CM; Wollner, M; Yang, JC | 1 |
| Gan, GN; Huang, C; Zhang, J | 1 |
| Dowlati, A; Finigan, JH; Foster, DG; Gardner, EE; Kern, JA; Kim, J; Mishra, R; Poirier, JT; Rivard, C; Rudin, CM; Tan, AC; Yu, H | 1 |
| Hirose, K; Kataoka, N; Kunimatsu, Y; Ogura, Y; Sato, I; Sugimoto, T; Tachibana, Y; Takeda, T; Tani, N | 1 |
| Azuma, K; Hoshino, T; Ishii, H; Kawahara, A; Matsuo, N; Tokito, T | 1 |
| Abdel-Rahman, O; Karachiwala, H; Morris, D; Tilley, D | 1 |
| Aggarwal, C; Cella, D; Dahlberg, SE; Feliciano, JL; Lash, BW; Leach, JW; Leal, TA; Mohindra, NA; Owonikoko, TK; Ramalingam, SS; Srkalovic, G; Steffen McLouth, LE; Wade, JL; Wagner, LI; Zhao, F | 1 |
| Guomin, X; Haifeng, W; Liping, Z; Qi, S; Xiping, W | 1 |
| Frampton, JE | 1 |
| Amini, A; Chang, JY; Chetty, IJ; Chun, SG; Donington, J; Edelman, MJ; Higgins, KA; Kestin, LL; Movsas, B; Rodrigues, GB; Rosenzweig, KE; Rybkin, II; Simone, CB; Slotman, BJ; Wolf, A | 1 |
| Cong, X; Gao, F; Liu, Z | 1 |
| Hou, X; Huang, Y; Liu, T; Luo, F; Wang, K; Zhang, L; Zhang, Z; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Hiroshima, K; Ikeda, JI; Motoi, N; Nakajima, T; Nakatani, Y; Ota, M; Yoshino, I | 1 |
| Chen, H; Horita, N; Takeshi, K | 1 |
| Caffo, O; Cattrini, C; Merz, V; Messina, C; Messina, M; Salati, M | 1 |
| Alatorre-Alexander, J; Califano, R; Cheng, Y; De Castro Carpeno, J; Deng, Y; Garassino, MC; Horn, L; Lam, S; Leal, T; Lee, JS; Liu, SV; Mansfield, AS; McCleland, M; Mok, T; Nishio, M; Orlandi, F; Phan, S; Reck, M; Reinmuth, N; Scherpereel, A | 1 |
| Ackermann, C; Califano, R; Ortega-Franco, A; Paz-Ares, L | 1 |
| Bu, J; Guo, L; Liang, S; Liu, J; Niu, Y; Wang, Q; Zhang, Z; Zheng, M | 1 |
| Ding, HY; Fang, L; Tong, YH; Xin, WX; Xu, GQ; Yang, GN; Zhang, B; Zhong, LK | 1 |
| Chen, B; Lin, J; Peng, J; Xue, L | 1 |
| Cho, YH; Choi, CM; Choi, SY; Jeong, GS; Ji, W; Kim, DS; Lee, JC; Rho, JK | 1 |
| Li, C; Li, W; Su, Z; Zhang, J; Zhang, X | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| Bogart, JA; Dobelbower, MC; Gao, J; Gaspar, LE; Heymach, JV; Komaki, R; Kuzma, C; Masters, GA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Chen, J; Qi, W; Zhao, S | 1 |
| Goyal, A; Khurana, AK; Rai, AC; Vangala, A | 1 |
| Bach, BA; Bentsion, D; Byers, LA; de Groot, P; Dunbar, M; Ellis, PM; Fujimoto, J; Gans, S; Gay, CM; Glasgow, J; Groen, HJM; He, L; Kang, K; Owonikoko, TK; Penkov, K; Sehgal, V; Sibille, A; Son, C | 1 |
| Chen, L; Chen, X; Fu, W; Wang, K; Zuyi, W | 1 |
| Chen, L; Chu, C; Fang, J; Guo, J; Guo, S; Huang, X; Huang, Y; Jiang, X; Li, Q; Lin, M; Liu, F; Liu, H; Liu, J; Pang, Q; Qiu, B; Wang, B; Wang, D; Xie, C; Yang, X; Zhu, Z | 1 |
| Burns, TF; Camidge, DR; Chen, C; Dowlati, A; Hann, CL; Koch, MM; Komarnitsky, P; Ludwig, C; Morgensztern, D; Nimeiri, H; Patel, M; Ward, PJ | 1 |
| Li, B; Li, J; Lou, H; Wang, L; Yang, YM | 1 |
| Ding, D; Hu, H; Huang, J; Li, S; Liao, M; Liu, A; Liu, J; Shi, Y; Tian, X; Zhu, Y | 1 |
| Bianco, A; D'Agnano, V; Della Gravara, L; Matera, MG; Perrotta, F; Rocco, D | 1 |
| Gu, D; Huang, P; Li, M; Lin, S; Luo, S; Rao, X; Wang, C; Weng, X; Xu, X | 1 |
| Bolm, L; Janssen, S; Käsmann, L; Rades, D | 1 |
| An, C; Guo, H; Jing, W; Kong, L; Liu, S; Wang, H; Zhang, Y; Zhu, H; Zhu, K | 1 |
| Akira, M; Asami, K; Atagi, S; Kawaguchi, T; Morimoto, M; Okishio, K; Omachi, N; Tamiya, A | 1 |
| Barbieri, F; Bertolini, F; Grizzi, G; Lococo, F; Mengoli, MC; Novello, S; Orsi, G; Rossi, G | 1 |
| Dean, RK; Gill, D; Nat, A; Subedi, R | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Besse, B; Dols, MC; Dubey, S; Glisson, B; Jain, R; Jiang, Y; Menon, H; Nackaerts, K; Orlov, S; Paz-Ares, L; Ramlau, R; Schupp, M; Tang, R; Zhang, Y; Zhu, M | 1 |
| Bonanno, L; Castiglione, F; Cavanna, L; Costanzo, R; Daniele, G; Di Maio, M; Favaretto, AG; Filipazzi, V; Gallo, C; Gebbia, V; Gridelli, C; Maiello, E; Maione, P; Morabito, A; Perrone, F; Piazza, E; Piccirillo, MC; Rocco, G; Rossi, A; Sandomenico, C | 1 |
| Appel, W; Ashcroft, L; Barlesi, F; Bezjak, A; Bhatnagar, A; Blackhall, F; Cardenal, F; Faivre-Finn, C; Fournel, P; Harden, S; Le Pechoux, C; Lorigan, P; McMenemin, R; Mohammed, N; O'Brien, M; Pantarotto, J; Snee, M; Surmont, V; Van Meerbeeck, JP; Woll, PJ | 1 |
| Aggarwal, C; Berman, AT; Cohen, RB; Evans, TL; Langer, C; Levin, WP; Lin, L; Rengan, R; Rwigema, JM; Simone, CB; Verma, V | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Cao, CL; Duan, PY; Li, L; Qu, FZ; Sun, B; Wang, G; Zhang, WJ | 1 |
| Delosh, R; Evans, D; Krushkal, J; Laudeman, J; Morris, J; Ogle, C; Parchment, R; Reinhart, R; Rubinstein, L; Selby, M; Silvers, T; Sonkin, D; Teicher, BA | 1 |
| Akeno, N; Callahan, M; He, D; Kim, RG; Lane, A; Miller, AL; Moulton, JS; Reece, AL; Wikenheiser-Brokamp, KA | 1 |
| Bai, F; Chen, L; Chen, Y; Xu, Y; Yang, X | 1 |
| Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW | 1 |
| Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Baker, K; Blackhall, F; Dive, C; Forster, M; Foy, V; Frese, KK; Gomes, F; Lallo, A; Schenk, MW | 1 |
| Bremnes, RM; Brunsvig, PF; Brustugun, OT; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Herje, M; Levin, N; Slagsvold, JE; Sundstrøm, SH; Valan, CD | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, BS; Kim, HG; Lee, KH; Lee, SH; Min, YJ; Park, K; Sun, JM; Yi, SY; Yun, HJ | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 2 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Balasubramaniam, S; Bates, SE; Bonner, WM; Bryla, C; Figg, WD; Fojo, T; Giaccone, G; Lee, MJ; Peer, CJ; Piekarz, RL; Rajan, A; Redon, CE; Tomita, Y; Trepel, JB | 1 |
| Choi, JH; Hahn, S; Heo, DS; Jang, JS; Kang, JH; Kim, BS; Kim, DW; Kim, HG; Kim, HK; Kim, JH; Kim, JS; Kim, SW; Kwon, JH; Lee, KH; Park, K; Ryoo, HM; Shin, SW | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Sakazaki, Y; Tokito, T; Tsuneyoshi, S; Yamada, K; Zaizen, Y | 1 |
| Darling, G; Durocher-Allen, LD; Ellis, PM; Goffin, JR; Ramchandar, K; Sun, A; Ung, YC | 2 |
| Abdel-Rahman, O | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Amemiya, K; Hirotsu, Y; Iijima, Y; Kakizaki, Y; Kobayashi, Y; Miyashita, Y; Mochizuki, H; Omata, M; Oyama, T; Tsutsui, T; Uchida, Y | 1 |
| Dómine Gómez, M; Fröhling, KP; Huber, RM; Kapp, K; Kollmeier, J; Mauri, C; Navarro, A; Ponce-Aix, S; Riera-Knorrenschild, J; Sadjadian, P; Schmidt, M; Thomas, M; Wiegert, E; Wittig, B; Wolf, M | 1 |
| Pujol, JL; Roch, B | 1 |
| Ding, B; Havel, L; Hochmair, MJ; Horn, L; Huemer, F; Johnson, ML; Kabbinavar, F; Krzakowski, M; Lam, S; Lin, W; Liu, J; Liu, SV; Lopez-Chavez, A; Losonczy, G; Mansfield, AS; Mok, T; Nishio, M; Reck, M; Sandler, A; Shames, DS; Szczęsna, A | 1 |
| Atrafi, F; Byers, LA; Calles, A; Camidge, DR; Chae, YK; Gabrail, NY; Garralda, E; Groen, HJM; He, L; Hoening, E; Hu, B; Komarnitsky, P; Lolkema, MP; Nuthalapati, S; Sangha, RS; Tian, T; Viteri, S | 1 |
| Anzai, M; Goto, N; Ishizuka, T; Kadowaki, M; Kodawara, T; Morikawa, M; Nakamura, T; Negoro, Y; Suehiro, Y; Tsukamoto, H; Umeda, Y; Watanabe, K; Yamashita, S; Yano, R; Yoshimura, M | 1 |
| Funaishi, K; Hattori, N; Ishiyama, S; Kawamoto, K; Matsumoto, N; Matsumoto, Y; Ohashi, N; Saito, N; Sakamoto, KI; Taniwaki, M; Yamasaki, M | 1 |
| Dean, S; Herath, D; Kosmider, S; McCracken, J | 1 |
| Blackhall, F; Faivre-Finn, C; Hatton, M; Locke, I; Mistry, H; Monnet, I; Salem, A | 1 |
| Anai, S; Iwama, E; Nakanishi, Y; Okamoto, I; Otsubo, K; Tanaka, K; Yoneshima, Y | 1 |
| Liu, JZ; Liu, WW; Liu, ZL; Wang, B | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Feng, J; Lin, J; Ye, Q | 1 |
| Chen, Q; Chen, R; Guo, L; Huang, W; Jia, L; Li, Y; Wu, Y; Zhu, Y | 1 |
| Albert, I; Barlesi, F; Bidoli, P; Cadranel, J; Chung, J; Drews, U; Fritsch, A; Govindan, R; Horn, L; Juhász, E; Kowalski, D; Novello, S; Reck, M; Robinet, G; Wagner, A | 1 |
| Bunn, PA; Pacheco, J | 1 |
| Chen, JN; Feng, T; Li, HM; Lin, DX; Ma, F; Tan, W; Xu, BH; Yang, J; Yin, LL; Yuan, P | 1 |
| Aben, N; Avelar, AT; Berns, A; Cozijnsen, M; de Vries, H; Nagel, R; Proost, N; van de Ven, M; van der Vliet, J; Wessels, LFA | 1 |
| Bai, L; Huang, J; Li, Q; Yang, Y; Zhang, N; Zhou, J; Zhou, K | 1 |
| Li, Z; Lu, S | 1 |
| Dumas, I; Ferrer, L; Guillem, P; Lattuca-Truc, M; Levra, MG; Moro-Sibilot, D; Pinsolle, J; Ruckly, S; Timsit, JF; Toffart, AC; Villa, J | 1 |
| Gou, J; He, H; Liu, X; Liu, Y; Luo, L; Qi, P; Tang, X; Yin, T; Zhang, Y | 1 |
| Gu, Y; Lin, X; Liu, J; Mai, S; Ouyang, M; Qin, Y; Xie, Z; Zhang, J; Zhou, C | 1 |
| Bahij, R; Halekoh, U; Hansen, O; Holmskov, K; Jeppesen, SS; Olsen, KE | 1 |
| Pan, YY; Shen, XB; Wang, W; Zhang, YX | 1 |
| Boutzios, G; Chatzellis, E; Kaltsas, G; Koumarianou, A; Tsavaris, N | 1 |
| Goto, K; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Jiang, SY; Karam, I; Khaira, M; Lee, CW; Schellenberg, D | 1 |
| Hasegawa, Y; Kataoka, K; Kimura, T; Kondo, M; Kondoh, Y; Nishiyama, O; Taniguchi, H; Watanabe, N | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Choi, EK; Jo, J; Jo, JS; Jung, SH; Kim, SW; Lee, DH; Lee, JS; Lee, SH; Park, K; Pyo, H; Sohn, HJ; Song, SY; Suh, C; Sun, JM | 1 |
| Bai, Y; Guo, L; Liu, H; Peng, J | 1 |
| Benoit, JP; Clavreul, A; Hureaux, J; Lagarce, F; Lautram, N; Saliou, B; Thomas, O; Urban, T | 1 |
| Levy, B; Saxena, A; Schneider, BJ | 1 |
| Ganti, AK; West, WW; Zhen, W | 1 |
| Fong, BM; Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Georgoulias, V; Karachaliou, N; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Stathopoulos, E; Trypaki, M | 1 |
| Hu, K; Li, L; Liu, H; Ma, M; Wang, H; Wang, M; Xu, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Bai, Y; Chen, Z; Guo, L; Li, Y; Xiao, F; Zeng, X | 1 |
| Bentzen, S; Bialas, M; Nowara, E; Suwinski, R; Tukiendorf, A; Wzietek, I | 1 |
| Albanell, J; Arpí, O; Arriola, E; Arumí-Uría, M; Cañadas, I; Dómine, M; García de Herreros, A; Menéndez, S; Mojal, S; Pijuan, L; Rojo, F; Rovira, A; Salido, M; Taus, Á; Zazo, S | 1 |
| Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV | 1 |
| Brouwers, EE; Huitema, AD; Kuck, EM; Rozemeijer, R; van Gorp, F; van Rens, MT | 1 |
| Fukuoka, M; Horai, T; Katakami, N; Nakagawa, K; Ohmatsu, H; Okamoto, H; Saijo, N; Sekine, I; Shibuya, M; Yokoyama, A | 1 |
| Choi, WH; Chun, SH; Hong, SH; Jeon, EK; Jung, CK; Kang, JH; Kim, JO; Kim, SJ; Kim, YK; Kim, YS; Lee, J; Yoo, IeR | 1 |
| Beck, JT; Besse, B; Camidge, DR; Dimitrijevic, S; Heist, RS; Johnson, BE; Miller, N; Mulatero, C; Papadmitrakopoulou, VA; Petrovic, K; Pylvaenaeinen, I; Schmid, P; Urva, S | 1 |
| Cai, S; Shi, A; Yu, R; Zhu, G | 1 |
| Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N | 1 |
| Caprario, LC; Kent, DM; Strauss, GM | 1 |
| Bover, I; Domine, M; Font, A; Galán, A; Gómez Codina, J; González Billalabeitia, E; Gúrpide, A; Isla, D; Lecumberri, R; López Vivanco, G; Rocha, E; Rosell, R; Vicente, V | 1 |
| Bradbury, PA; Ellis, PM; Goss, GD; Laurie, SA; Olivo, M; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Connis, N; Cope, L; Dobromilskaya, I; Gallia, GL; Gardner, EE; Hann, CL; Poirier, JT; Rudin, CM | 1 |
| Maggs, FG | 1 |
| Chen, X; Li, W; Ma, KW; Wang, X; Wang, YZ | 1 |
| Yano, S | 1 |
| Kobayashi, S; Nakagawa, K; Nakamatsu, K; Nishimura, Y; Okamoto, I; Okamoto, K; Takeda, K; Takeda, M | 1 |
| Amatulli, M; Balderes, P; Brennan, L; Burtrum, D; Credille, KM; Damoci, CB; DeLigio, JT; Duignan, IJ; Kotanides, H; Lebron, MB; Loizos, N; O'Mahony, M; Paz, K; Persaud, K; Prewett, MC; Schwartz, KD; Starodubtseva, M; Surguladze, D; Zhang, Y | 1 |
| Chen, M; Ni, J; Qi, HW; Xie, HK; Xu, JF; Zhang, J; Zheng, H; Zhou, CC; Zhu, J | 1 |
| Albert, I; Ao-Baslock, A; Berger, MS; Blakely, LJ; Kazarnowicz, A; Kovacs, P; Langer, CJ; Moezi, MM; Pajkos, G; Pathak, AK; Ross, HJ; Schnyder, J; Schreeder, MT; Somfay, A; Zatloukal, P | 1 |
| Chen, Z; Guo, L; Guo, Y; Huang, J; Li, M; Li, X; Luo, L; Zhang, F; Zhu, W | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Beumer, J; Chen, A; Chen, Z; Christner, SM; Deng, X; Doho, GH; Khuri, FR; Kim, S; Kowalski, J; Li, C; Owonikoko, TK; Ramalingam, SS; Rossi, MR; Sica, GL; Strychor, S; Sun, SY; Switchenko, JM; Yue, P; Zhang, G | 1 |
| Ak, G; Akcay, M; Bayman, E; Etiz, D | 1 |
| Akhurst, T; Cullinane, C; Eu, P; Hicks, RJ; Lewin, J; Mileshkin, L; Rao, A; Waldeck, K; Watkins, DN | 1 |
| Ausch, C; Bajna, E; Brenner, S; Buxhofer-Ausch, V; Hamilton, G; Jäger, W; Klameth, L; Reiner, A; Riha, J; Schölm, M; Thalhammer, T | 1 |
| Eba, J; Misumi, Y; Nakamura, K; Ohe, Y; Okamoto, H; Shibata, T; Shimokawa, T; Yamamoto, N | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Han, J; Ji, JH; Kim, KM; Park, K; Sun, JM | 1 |
| Chang, J; Du, Z; Li, D; Lin, D; Shen, H; Tan, W; Wei, L; Wu, C; Wu, T; Xu, B; Yu, D; Yuan, P | 1 |
| Huang, H; Kang, H; Li, C; Peng, B; Peng, Y; Wang, D; Xiong, Y; Xu, M; Yang, X; Zhou, Z | 1 |
| Chen, L; Chen, Y; Pan, B; Song, H; Wang, R; Xu, Y | 1 |
| Auliac, JB; Baize, N; Berard, H; Chouaid, C; Falchero, L; Gervais, R; Le Caer, H; Monnet, I; Olivero, G; Thomas, P | 1 |
| Bai, Y; Guo, L; Liu, H; Wang, W | 1 |
| Cai, XW; Fan, M; Fu, XL; Hong, LZ; Liu, Q; Mao, JF; Wu, KL; Xia, B; Yang, HJ; Zhao, KL; Zhu, ZF | 1 |
| Bai, Y; Lan, H; Luo, S | 1 |
| Chen, P; Chen, Z; Guo, S; Hu, C; Huang, C; Li, B; Li, L; Li, W; Liao, M; Lu, S; Luo, Y; Song, X; Wu, G; Xu, L; Yu, Y; Zhang, L; Zhang, Y; Zhou, C | 1 |
| Barlesi, F; Barre, P; Chatellain, P; Dayen, C; Derollez, M; Fournel, P; Herman, D; Jeannin, G; Lamy, PJ; Langlais, A; Lavole, A; Le Caer, H; Molinier, O; Morin, F; Moro-Sibilot, D; Mourlanette, P; Oster, JP; Pujol, JL; Quoix, E; Renault, A; Souquet, PJ; Zalcman, G | 1 |
| Costa, DB; Desai, NV; Folch, E; Gangadharan, SP; Huberman, MS; Karp, RS; Kent, MS; Le, X; Majid, A; Rangachari, D; VanderLaan, PA | 1 |
| Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE | 1 |
| Baldi, L; Boni, C; Braglia, L; Gnoni, R; Pagano, M; Savoldi, L; Zanelli, F | 1 |
| Choi, KH; Hwang, KE; Jeong, ET; Jung, JW; Kim, HR; Oh, SJ; Park, MJ; Shon, YJ | 1 |
| Bongiovanni, A; Burgio, MA; Califano, R; Carloni, F; Casanova, C; Cavallo, G; Di Battista, M; Genestreti, G; Kazushige, W; Kenmotsu, H; Korkmaz, T; Metro, G; Roopa, K; Scarpi, E; Selcuk, S; Tiseo, M | 1 |
| Aggarwal, C; Belani, CP; Dahlberg, SE; Dowell, J; Gerber, DE; Hann, CL; Khan, SA; Moss, RA; Owonikoko, TK; Ramalingam, SS | 1 |
| Harada, M; Inoue, A; Ishida, T; Kinoshita, I; Maemondo, M; Mori, Y; Morikawa, N; Nakagawa, T; Nukiwa, T; Oizumi, S; Saito, R; Sugawara, S; Suzuki, T; Taima, K; Watanabe, H | 1 |
| Artal, A; Barneto, I; De Castro, J; Esteban, E; Gascó, P; Gasent, JM; Montalar, J; Muñoz-Langa, J; Sanchez, A; Vidal, S | 1 |
| Liang, G; Xu, T; Yang, L; Zhang, F | 1 |
| Bianco, V; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Martellucci, I; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L | 1 |
| Chen, P; Jiang, Q; Li, J; Tang, XP; Zhu, LR | 1 |
| Hoffmann, L; Khalil, AA; Knap, MM; Moeller, DS; Winther-Larsen, A | 1 |
| Ge, SL; Tian, DD; Yang, N; Zhang, CL; Zhang, JR | 1 |
| Akarsu, Z; Duman, E; Gunduz, S; Inal, A; Kaya, V; Ozturk, D; Yildirim, M; Yildiz, M | 1 |
| Haixia, P; Honglin, H; Yifeng, B | 1 |
| Nosaki, K; Seto, T | 1 |
| Aasebø, U; Aksnessæther, BY; Bremnes, RM; Brunsvig, PF; Brustugun, OT; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Hornslien, K; Liaaen, ED; Sundstrøm, S; Tollåli, T | 1 |
| Čebron Lipovec, N; Čufer, T; Grabnar, I; Mrhar, A; Režonja Kukec, R; Vovk, T | 1 |
| Das, S; Dunphy, FR; Gu, L; Kelsey, CR; Marks, LB; Ready, NE | 1 |
| Bogart, JA; Crawford, J; Gu, L; Pang, HH; Ready, NE; Salama, JK; Schild, SE; Vokes, EE; Wang, X | 1 |
| Aoyagi, H; Chubachi, S; Ikemura, S; Iwami, E; Matsuzaki, T; Nakajima, T; Terashima, T | 1 |
| Janssen, S; Kaesmann, L; Rades, D; Schild, SE | 1 |
| Biner Uslu, I; Dikmen, A; Erdoğan, Y; Yilmaz Demirci, N; Yılmaz, A; Yilmaz, Ü | 1 |
| Cheng, Y; Feng, J; Han, B; Hao, X; Hou, M; Hu, C; Li, W; Liu, X; Liu, Y; Luo, X; Qin, S; Sun, Y; Wan, H; Wang, J; Xia, Z; Xiu, Q; Zhang, H; Zhang, L; Zhu, Y | 1 |
| Chen, L; Chen, Y; Feng, X; Peng, L; Wang, J; Zhong, D | 1 |
| Belani, CP; Chen, HX; Dahlberg, SE; Fleisher, M; Hann, CL; Monga, M; Ramalingam, SS; Rudin, CM; Schiller, JH; Shanks, JC; Sturtz, K; Takebe, N; Tester, WJ; Velasco, MR | 1 |
| Arriola, E; Cave, J; Cross, N; Danson, S; Galea, I; Geldart, T; Griffiths, R; Hamid, D; Maishman, T; Mulatero, C; Nolan, L; Ottensmeier, C; Potter, V; Stanton, L; Wheater, M; Woll, PJ | 1 |
| Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N | 1 |
| Cheng, Y; Cui, HX; Li, ZL; Ma, LX; Sun, SY; Yang, CL | 1 |
| Hatfield, LA; Huskamp, HA; Lamont, EB | 1 |
| Wolin, EM | 1 |
| de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
| Fujimoto, S; Imai, H; Kaira, K; Minato, K; Mori, K; Watase, N; Yamada, M | 1 |
| Aerts, J; Akerley, W; Fairchild, J; Felip, E; Gold, K; Havel, L; Horn, L; Kim, SW; Kong Sanchez, T; Lorigan, P; Luft, A; Nakagawa, K; Pietanza, MC; Pieters, A; Reck, M; Spigel, D; Szczesna, A; Thomas, M; Wu, YL; Zielinski, C | 1 |
| Janssen, S; Käsmann, L; Rades, D | 1 |
| Feng, T; Huang, Y; Li, HM; Lin, DX; Ma, F; Tan, W; Tan, WW; Xu, BH; Yang, J; Yu, DK; Yuan, P | 1 |
| Aasebø, U; Bremnes, RM; Brunsvig, P; Brustugun, OT; Fløtten, Ø; Grønberg, BH; Halvorsen, TO; Kaasa, S; Sundstrøm, S | 1 |
| Berger, MF; Fleisher, M; Holodny, AI; Kris, MG; Krug, LM; Litvak, AM; Ng, KK; Pietanza, MC; Rudin, CM; Sima, CS; Teitcher, JB; Varghese, AM; Won, HH; Woo, KM | 1 |
| Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J | 1 |
| Jeong, JS; Kim, SR; Lee, JH; Lee, YC | 1 |
| Fujimoto, S; Imai, H; Kaira, K; Kazama, T; Minato, K; Mori, K; Watase, N; Yamada, M | 1 |
| Braun, F; Burger, M; Catusse, J; Kayser, G; Reichardt, W; Taromi, S; von Elverfeldt, D; Weber, WA; Zeiser, R | 1 |
| Asao, T; Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Kitahara, S; Nokihara, H; Ohe, Y; Okuma, HS; Sunami, K; Yamamoto, N | 1 |
| Adam, V; Balvan, J; Dostalova, S; Heger, Z; Krizkova, S; Masarik, M; Moulick, A; Polanska, H; Raudenska, M | 1 |
| Barbolosi, D; Barlesi, F; El Cheikh, R; Faivre, C | 1 |
| Shi, A; Shi, C; Song, M; Wang, X; You, J; Yu, H; Yu, R; Zheng, Y; Zhu, G | 2 |
| Ambrosio, F; Ardizzoni, A; Baldini, E; Boni, L; Brighenti, M; Camerini, A; Chiari, R; Cinieri, S; D'Alessandro, V; Dazzi, C; Defraia, E; Grossi, F; Riccardi, F; Tibaldi, C; Tiseo, M; Trolese, AR; Turolla, GM; Zanelli, F; Zilembo, N | 1 |
| Neal, JW; Wakelee, HA | 1 |
| Du, ZL; Feng, T; Huang, Y; Li, HM; Lin, DX; Ma, F; Tan, W; Tan, WW; Xu, BH; Yang, J; Yu, DK; Yuan, P | 1 |
| Flynt, A; Hamid, O; McCleod, M; Polzer, J; Roberson, S; Salgia, R; Spigel, DR; Stille, JR; Weaver, RW | 1 |
| Crosse, B; Cullen, M; Fife, KM; Hackshaw, A; Harden, S; Middleton, G; Muthukumar, D; Nash, S; Ngai, Y; Ottensmeier, CH; Schmid, P; Seckl, MJ; Taylor, P; Thompson, J | 1 |
| Deng, Z; Gu, Y; Li, J; Lin, S; Ma, J; Ma, W; Xu, J; Yao, X; Zhang, H | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Fan, M; Fu, XL; Liu, D; Wu, KL; Zhang, J; Zhao, KL; Zhao, WX; Zhu, ZF | 1 |
| Artal-Cortes, A; Barneto, I; Camps, C; Carrato, A; Gómez-Codina, J; González-Larriba, JL; Isla, D; Rosell, R; Safont, MJ; Sirera, R | 1 |
| Algara, M; Fernández-Velilla, E; Foro, P; Lacruz, M; López, JL; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takezawa, K | 1 |
| de Lima, MC; Moreira, JN; Santos, A; Sarmento-Ribeiro, AB; Simões, S | 1 |
| Eisen, T; Ferry, DR; Gilligan, D; Gower, NH; Harper, PG; Hocking, M; James, LE; Lee, SM; Prendiville, J; Qian, W; Rudd, RM; Spiro, S | 1 |
| Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J | 1 |
| Bao, Y; Chen, M; Chen, YY; Gao, JM; He, H; Hu, X; Liu, Y; Poudel, S; Sun, ZW; Wang, WH; Wang, Y; Zhang, L; Zhuang, TT | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Cordier, JF; Cottin, V; Girard, N; Lapalus, MG; Tronc, F | 1 |
| Aguero, EG; Fortney, JA; Garrett-Mayer, E; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM | 1 |
| Shao, S; Wang, J; Wang, Q; Wang, S; Wang, W; Wang, Y | 1 |
| Bregni, M; Pedrazzoli, P | 1 |
| Hann, CL; Rudin, CM | 1 |
| Baggstrom, MQ; Burdette-Radoux, S; Govindan, R; Green, MR; Hodgson, L; Vokes, EE; Wang, X | 1 |
| Kane, SE; Mudry, RR; Sadava, D; Still, DW | 1 |
| Gatzemeier, U; Heigener, DF; Jäger, E; Manegold, C; Saal, JG; Zuna, I | 1 |
| Bono, K; Fujita, Y; Ito, S; Kawabata, A; Kawaishi, M; Kuwano, K; Mikami, J; Numata, T; Tamura, K; Wakui, H; Yumino, Y | 1 |
| Amaro, T; Arúajo, AM; Azevedo, I; Barata, F; Coelho, AL; Figueiredo, A; Mendez, JC; Soares, M; Sousa, B | 1 |
| Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Crowley, JJ; Gandara, DR; Gaspar, LE; Goldberg, Z; Lara, PN; Le, QT; Moon, J; Moore, DF; Redman, M; Williamson, SK | 1 |
| Baud, M; Chouaïd, C; Febvre, M; Lebeau, B; Masanès, MJ | 1 |
| Baba, T; Hanagiri, T; Ichiki, Y; Ohga, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasuda, M; Yasumoto, K | 1 |
| Hansen, KH; Hansen, O; Sørensen, P | 1 |
| Choe, DH; Kang, MS; Kim, CH; Lee, JC; Noh, GY | 1 |
| Blakely, J; Ciuleanu, T; Dediu, M; Guba, SC; Hanauske, AR; Hong, S; Jassem, J; Karaseva, NA; Konduri, K; Lorigan, P; Obasaju, CK; Reck, M; Serwatowski, P; Smit, EF; Socinski, MA; Szczesna, A; Thatcher, N; Visseren-Grul, C | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Boersma, L; Bootsma, G; De Ruysscher, D; Dehing-Oberije, C; Dingemans, AM; Geraedts, W; Hochstenbag, M; Lambin, P; Oellers, M; Pitz, C; Rhami, A; Simons, J; Snoep, G; Teule, J; Thimister, W; van Loon, J; Wanders, R | 1 |
| Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Fu, J; Hanes, J; Tang, BC; Watkins, DN | 1 |
| Adjei, AA; Baas, P; Choy, H; Gandara, DR; Gaspar, LE; Goss, G; Lara, PN; Saijo, N; Sangha, R; Schiller, JH; Vokes, EE | 1 |
| Arvelo, F; Assayag, F; Bourgeois, Y; Daniel, C; Decaudin, D; Froget, B; Legrier, ME; Livartowski, A; Némati, F; Poupon, MF | 1 |
| Dahlberg, SE; Dowlati, A; Horn, L; Moore, DF; Murren, JR; Sandler, AB; Schiller, JH | 1 |
| Fukuoka, M; Nakagawa, K; Nishimura, Y; Okamoto, I; Okamoto, K; Tachibana, I; Takezawa, K | 1 |
| Inagaki, H; Iwashima, Y; Kusumoto, S; Kutsuna, T; Maeno, K; Miyazaki, M; Nakamura, A; Nakao, M; Oguri, T; Ota, C; Ozasa, H; Sato, S; Takakuwa, O; Ueda, R; Uemura, T | 1 |
| Musallam, KM; Taher, AT | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Ochi, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Adachi, M; Hirose, T; Nakamura, A; Ohnishi, T; Okuda, K; Yamaoka, T; Yashiki, C | 1 |
| Enting, D; Forster, M; Nicholson, AG; O'Brien, M; Popat, S | 1 |
| Endo, K; Hara, Y; Hirabayashi, M; Hirai, T; Hirano, K; Narabayashi, T; Terashita, S | 1 |
| Gopalan, D; Raj, V; Shaida, N | 1 |
| Manapov, F | 1 |
| Arimoto, T; Hara, H; Iwasaki, Y; Kubota, Y; Nakanishi, M; Ueda, M | 1 |
| Govindan, R; Subramanian, J | 1 |
| Adachi, M; Hirose, T; Kusumoto, S; Nakamura, A; Ohmori, T; Shirai, T; Sugiyama, T; Yashiki, C | 1 |
| Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN | 1 |
| Cardenal, F; Cisar, L; Domine, M; Gorbunova, V; Moiseyenko, V; Soria, JC; Szczesna, A; Thomas, M; Zatloukal, P; Zhang, X | 1 |
| Hirashima, T; Kawase, I; Kobayashi, M; Kusunoki, Y; Matsui, K; Morishita, N; Okamoto, N; Sasada, S; Suzuki, H; Tamiya, M | 1 |
| Bai, Y; Guo, L; Guo, Y; Liu, Y; Sun, Y; Xiao, F | 1 |
| Charpidou, A; Gkiozos, I; Makrilia, N; Stratakos, G; Syrigos, K; Tsagouli, S; Tsimpoukis, S; Vassias, A | 1 |
| Beckles, M; Chao, D; Lang, B; McCabe, DJ; Ng, K; Simister, RJ | 1 |
| Jalalvand, E; Kaminskyy, V; Surova, O; Vaculova, A; Zhivotovsky, B | 1 |
| Albelda, SM; Burny, A; Crisanti, C; Crisanti, MC; Hubaux, R; Kapoor, V; Mascaux, C; Vandermeers, F; Willems, L | 1 |
| Guan, Y; Lin, D; Liu, Y; Liu, Z; Ott, J; Shen, Y; Wu, C; Xu, B; Yu, D; Yuan, P | 1 |
| Fijuth, J; Jesien-Lewandowicz, E; Kordek, R; Spych, M | 1 |
| Fukunaga, K; Hajiro, T; Hashimoto, S; Ikezoe, K; Kaji, Y; Minakuchi, M; Nakajima, T; Okumura, N; Sakuramoto, M; Sato, E; Sugimura, M; Taguchi, Y; Tanaka, E; Tanizawa, K; Yasuda, T | 1 |
| Endo, M; Kaira, K; Murakami, H; Naitou, T; Nakamura, Y; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Le Péchoux, C; Paumier, A | 1 |
| Baandrup, L; Hauggaard, A; Holm, B; Winberg, BH | 1 |
| Bao, Y; Chen, J; Chen, M; Cheng, Y; He, H; Hu, X; Li, K; Liang, Y; Liu, Y; Sun, Z; Wang, F; Wang, W; Wang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhuang, T | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Baka, S; Georgoulias, V; Gerogianni, A; Kalbakis, K; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Pavlakou, G; Tsaroucha, E; Vamvakas, L; Veslemes, M | 1 |
| Chansky, K; Crowley, J; Fukuda, H; Gandara, DR; Lara, PN; Natale, R; Redman, MW; Saijo, N; Shibata, T; Tamura, T | 1 |
| Joseph, B; Muppani, NR; Nyman, U; Zhivotovsky, B | 1 |
| Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V | 1 |
| dos Santos, LV; Lima, CS; Lima, JP; Sasse, AD; Sasse, EC | 1 |
| Braidotti, P; Fabbri, A; Galetta, D; Manzotti, M; Pelosi, G; Perrone, F; Sonzogni, A; Spaggiari, L; Veronesi, G; Viale, G | 1 |
| Guo, S; Liang, Y; Zhou, Q | 1 |
| Binder, D; Caca, K; Eberhardt, WE; Fischer von Weikersthal, L; Fischer, B; Fischer, JR; Gauler, TC; Hortig, P; Kaufmann, C; Keilholz, U; Link, H; Martus, P; Schmittel, A; Sebastian, M | 1 |
| Engel-Riedel, W; Gieseler, F; Guetz, S; Kellner, O; Nagel, S; Schuette, W; Schumann, C | 1 |
| Azuma, A; Gemma, A; Kitamura, K; Kosaihira, S; Kudoh, S; Kuribayashi, H; Minegishi, Y; Mizutani, H; Okano, T; Seike, M; Yoshimura, A | 1 |
| Ashcroft, L; Blackhall, F; Califano, R; Colaco, R; Faivre-Finn, C; Lorigan, P; Sheikh, H; Taylor, P; Thatcher, N | 1 |
| Maceneaney, P; Moylan, EJ; O'Reilly, SP; Power, DG; Ryan, SA | 1 |
| Cegovnik, U; Kern, I; Korošec, P; Košnik, M; Rijavec, M; Silar, M; Triller, N | 1 |
| Berger, M; Blackhall, F; Cummings, J; Dean, EJ; Dive, C; Ranson, M; Roulston, A | 1 |
| Adiguzel, I; Fang, L; Faoro, L; Huang, JE; Karlin, DA; Scappaticci, FA; Socinski, MA; Spigel, DR; Townley, PM; Waterhouse, DM | 1 |
| Daignault, S; Dy, GK; Gadgeel, SM; Kalemkerian, GP; Ramnath, N; Schneider, BJ; Wozniak, AJ | 1 |
| Chen, DF; Feng, QF; Liang, J; Ou, GF; Wang, LH; Xiao, ZF; Zhang, HX; Zhang, XR; Zhou, ZM; Zhu, H | 1 |
| Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A | 1 |
| Brenton, JD; Cummings, NM; Lawson, MH; Murphy, G; Rassl, DM; Rintoul, RC; Russell, R | 1 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Baud, M; Chouaïd, C; Febvre, M; Lebeau, B; Masanes, MJ; Mokhtari, T | 1 |
| Dingemans, AM; Giaccone, G; Lee, JH; Pham, T; Voeller, DM; Voortman, J; Wang, Y | 1 |
| Chen, LK; Dinglin, XX; Huang, H; Liao, H; Liu, GZ; Wei, WD; Xu, GC; Zeng, YD | 1 |
| Agama, K; Bates, SE; Giaccone, G; Komlodi-Pasztor, E; Luchenko, VL; Murphy, RF; Pommier, Y; Salcido, CD; Varticovski, L; Zhang, Y | 1 |
| Ashcroft, L; Blackhall, F; Califano, R; Colaco, R; Faivre-Finn, C; Hulse, P; Lorigan, P; Sheikh, H; Taylor, P; Thatcher, N | 1 |
| Ciuleanu, T; Guba, SC; Hong, S; Hozak, RR; Karaseva, NA; Lorigan, P; Mullaney, BP; Myrand, SP; Ohannesian, D; Powell, E; Reck, M; Scagliotti, GV; Smit, EF; Socinski, MA; Szczesna, A; Thatcher, N; von Pawel, J | 1 |
| Jin, S; Shao, N; Zhu, W | 1 |
| Cho, YJ; Duk Lee, J; Go, SI; Hwang, YS; Jeong, YY; Kim, DC; Kim, HC; Ko, GH; Lee, GW; Lee, JH; Lee, JS; Oh, S; Yang, JW | 1 |
| Berger, MS; Blakely, J; Chiappori, AA; Chu, QS; Moezi, MM; Ross, HJ; Salgia, R; Schnyder, J; Schreeder, MT; Stephenson, JJ; Subramaniam, DS | 1 |
| Belda-Iniesta, C; Cejas, P; De Castro Carpeño, J; Feliu, J; López, R; Moreno, V; Nistal, M; Sereno, M | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Guan, QL; Jiang, L; Mi, DH; Wang, J; Yang, KH | 1 |
| Cufer, T; Kern, I; Knez, L; Košnik, M; Ovčariček, T; Sadikov, A; Sodja, E | 1 |
| Bradley, JD; Choy, H; Curran, WJ; Ettinger, DS; Glisson, BS; Komaki, R; Langer, CJ; Paulus, R; Sause, WT; Videtic, GM | 1 |
| Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L | 1 |
| Aziz, SI; Khattak, MA; Ladipeerla, N; Pittman, K; Usmani, Z | 1 |
| Dong, XJ; Li, LY; Wang, MZ; Xia, Y; Zhang, L; Zhang, XT; Zhao, J; Zhong, W | 1 |
| Eijk, PP; Groenendijk, MR; Paul, MA; Postmus, PE; Smit, EF; Thunnissen, E; van de Wiel, MA; Ylstra, B | 1 |
| Guven, M; Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Nas, N; Urakci, Z | 1 |
| Han, TJ; Heo, DS; Kim, HJ; Kim, YW; Lee, SH; Wu, HG | 1 |
| Acker, T; Banik, N; Bogenrieder, T; Eberhardt, F; Eschbach, C; Fink, TH; Heigener, DF; Huber, RM; Hummler, S; Ittel, T; Schroeder, M; Schweisfurth, H; Steinhauer, EU; Virchow, JC; Waller, C; Wolf, M | 1 |
| Dai, J; Han, M; Jia, J; Jiang, M; Lin, Q; Liu, Q; Xu, X; Zhang, Y | 1 |
| Guba, SC; Liepa, AM; Lorigan, P; Peterson, P; Reck, M; Smit, EF; Socinski, MA; Szutowicz-Zielinska, E; Thatcher, N; Winfree, KB | 1 |
| Buschmann, MD; Gal, S; Jean, M; Li, Z; Liao, S; Merzouki, A; Slilaty, SN; Young, RS | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Spigel, DR | 1 |
| Dimitroulis, J; Kosmas, Ch; Stathopoulos, GP; Stathopoulos, J; Trafalis, D; Tsavdaridis, D | 1 |
| Li, AW; Liu, JM; Luo, J; Wu, FY; Zheng, D | 1 |
| Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
| Bootsma, G; Borger, J; De Ruysscher, D; Dingemans, AM; Geraedts, W; Lambin, P; Lunde, R; Pitz, C; Reymen, B; van Baardwijk, A; Van Loon, J; Wanders, R | 1 |
| Hou, M; Li, Z; Pu, D; Zeng, X | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Beck, R; Ellis, PM; Fandi, A; Jungnelius, U; Shepherd, FA; Zhang, J | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N | 1 |
| Su, Y | 1 |
| Chabaud, S; Court-Fortune, I; Falandry, C; Fournel, C; Freyer, G; Girard, P; Ribba, B; Souquet, PJ; Tod, M; Tranchand, B; Trillet-Lenoir, V; You, B | 1 |
43 review(s) available for etoposide and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2021 |
Durvalumab: A Review in Extensive-Stage SCLC.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
Update 2021: Management of Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
[MDT Treatment of Small Cell Lung Cancer Complicated with Adenocarcinoma:
A Case Report and Literature Review].
Topics: Adenocarcinoma of Lung; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Research Design; Small Cell Lung Carcinoma | 2022 |
Evolving role of immunotherapy in small cell lung cancer.
Topics: Etoposide; Humans; Immunologic Factors; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review.
Topics: Aged; Carboplatin; Etoposide; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Small Cell Lung Carcinoma | 2023 |
Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Cisplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Small Cell Lung Carcinoma | 2023 |
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cervix Uteri; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging; Platinum; Rare Diseases; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | 2023 |
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Network Meta-Analysis; Platinum; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2023 |
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Small Cell Lung Carcinoma; Survival Analysis | 2023 |
Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Drug Therapy; Etoposide; Humans; Immunotherapy; Small Cell Lung Carcinoma | 2020 |
Atezolizumab: A Review in Extensive-Stage SCLC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Lung Neoplasms; Progression-Free Survival; Quality of Life; Small Cell Lung Carcinoma | 2020 |
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2020 |
Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2021 |
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma; Tumor Microenvironment | 2021 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
Acute pancreatitis induced by etoposide-lobaplatin combination chemotherapy used for the treatment of lung cancer: A case report and literature review.
Topics: Acute Disease; Antineoplastic Agents; Cyclobutanes; Diagnosis, Differential; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Pancreatitis; Small Cell Lung Carcinoma | 2017 |
Targeting DNA damage in SCLC.
Topics: Aurora Kinases; Azepines; Benzimidazoles; Carbolines; Cell Cycle Checkpoints; Cell Proliferation; Cytotoxins; DNA Damage; DNA Repair; Etoposide; Genomic Instability; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Rad51 Recombinase; Small Cell Lung Carcinoma | 2017 |
Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
[Small cell lung cancer and immuno-oncologic agents: End of the cisplatin - etoposide era?]
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Molecular Targeted Therapy; Small Cell Lung Carcinoma | 2018 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Hematologic Diseases; Humans; Incidence; Irinotecan; Lung Neoplasms; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vomiting | 2018 |
Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Clinical Protocols; Clinical Trials as Topic; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2019 |
Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2019 |
Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Colonic Neoplasms; Diagnosis, Differential; Diagnostic Imaging; Etoposide; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Platinum Compounds; Prognosis; Receptors, Somatostatin; Retrospective Studies; Small Cell Lung Carcinoma | 2013 |
Systemic therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Lung Neoplasms; Platinum; Recurrence; Small Cell Lung Carcinoma | 2013 |
Current concepts in the management of small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome | 2013 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:
A Network Meta-analysis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2016 |
Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cisplatin; Disease Management; Etoposide; Everolimus; Humans; Lung Neoplasms; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Pneumonectomy; Small Cell Lung Carcinoma; Somatostatin | 2017 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Management of small-cell lung cancer: incremental changes but hope for the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2008 |
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Randomized Controlled Trials as Topic; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome; Vincristine | 2009 |
[Renal salt-wasting syndrome progressing to severe hyponatremia after chemotherapy--a case report].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Hyponatremia; Kidney Diseases; Lung Neoplasms; Small Cell Lung Carcinoma; Syndrome | 2010 |
Radiotherapy in small-cell lung cancer: where should it go?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Early Detection of Cancer; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Radiotherapy; Small Cell Lung Carcinoma | 2010 |
Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma | 2010 |
Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
114 trial(s) available for etoposide and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Follow-Up Studies; Humans; Immunotherapy; Lung Neoplasms; Markov Chains; Medicare; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; United States | 2021 |
Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2021 |
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Research Design; Small Cell Lung Carcinoma | 2022 |
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Convalescence; Deglutition Disorders; Dose Fractionation, Radiation; Dyspnea; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Patient Reported Outcome Measures; Quality of Life; Radiotherapy; Small Cell Lung Carcinoma | 2022 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; China; Etoposide; Humans; Indoles; Lung Neoplasms; Platinum; Prospective Studies; Quinolines; Small Cell Lung Carcinoma | 2022 |
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2022 |
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Immune Checkpoint Inhibitors; Ligands; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma | 2022 |
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Small Cell Lung Carcinoma | 2022 |
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Topics: Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Prospective Studies; Small Cell Lung Carcinoma; Turtles | 2023 |
Preliminary results of randomized phase II study of etoposide plus lobaplatin or etoposide plus cisplatin with concurrent thoracic radiotherapy in the treatment of limited-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagitis; Etoposide; Humans; Lung Neoplasms; Radiation Pneumonitis; Small Cell Lung Carcinoma | 2023 |
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia | 2023 |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Etoposide; Humans; Immunotherapy; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2023 |
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
Topics: Etoposide; Humans; Hypertension; Lung Neoplasms; Prospective Studies; Proteinuria; Small Cell Lung Carcinoma; Stomatitis | 2023 |
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan | 2023 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nitro Compounds; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult | 2019 |
Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Prospective Studies; Pulmonary Fibrosis; Radiotherapy Dosage; Research Report; Small Cell Lung Carcinoma | 2020 |
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Sweden; Treatment Outcome | 2020 |
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Small Cell Lung Carcinoma | 2020 |
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Analysis | 2021 |
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Radiotherapy Dosage; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
Topics: Adult; Aged; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Dose Hypofractionation; Small Cell Lung Carcinoma | 2021 |
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Etoposide; Humans; Immunoconjugates; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2017 |
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Disease Management; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2017 |
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation Pneumonitis; Small Cell Lung Carcinoma; Survival Rate | 2017 |
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2018 |
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed | 2018 |
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Etoposide; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2018 |
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2018 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Republic of Korea; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2019 |
Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2018 |
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Follow-Up Studies; Humans; Immunosuppressive Agents; Immunotherapy; International Agencies; Leflunomide; Lung Neoplasms; Maintenance Chemotherapy; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Toll-Like Receptor 9 | 2018 |
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Small Cell Lung Carcinoma | 2018 |
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Time Factors | 2019 |
The effects of carboplatin and etoposide on advanced small cell lung cancer and serum tumor markers in correlation with long-term survival rate.
Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Endostatins; Etoposide; Female; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Small Cell Lung Carcinoma; Sulfoxides | 2019 |
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost of Illness; Cost-Benefit Analysis; Double-Blind Method; Etoposide; Health Care Costs; Humans; Lung Neoplasms; Neoplasm Staging; Placebos; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Analysis | 2019 |
Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival; Treatment Failure | 2013 |
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2014 |
A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quality of Life; Small Cell Lung Carcinoma; Survival Rate | 2014 |
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Everolimus; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Sirolimus; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome | 2014 |
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2013 |
NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma | 2014 |
A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Gamma Rays; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Radiation Dosage; Small Cell Lung Carcinoma; Thorax | 2014 |
Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2014 |
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Time Factors | 2014 |
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Patient Selection; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2015 |
Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Radiosurgery; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vincristine | 2015 |
Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Small Cell Lung Carcinoma | 2015 |
A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Endostatins; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Young Adult | 2015 |
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Epirubicin; Etoposide; Female; France; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome; Young Adult | 2015 |
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2015 |
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Etoposide; Fatigue; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Thrombocytopenia | 2015 |
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Norway; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Esophagus; Etoposide; Female; Heart; Humans; Lung; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organ Sparing Treatments; Quality of Life; Radiation Injuries; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma | 2015 |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Pyrroles; Retrospective Studies; Small Cell Lung Carcinoma; Sunitinib | 2016 |
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2016 |
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Pyridines; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Biomarkers, Tumor; Carboplatin; Etoposide; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2016 |
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Diarrhea; Etoposide; Female; Humans; Ipilimumab; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Comorbidity; Cranial Irradiation; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2016 |
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cisplatin; Etoposide; Female; Hedgehog Proteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Neoplastic Cells, Circulating; Pyridines; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma | 2017 |
[A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
Topics: Adult; Aged; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Safety; Small Cell Lung Carcinoma; Time Factors | 2017 |
[Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
Topics: Adult; Aged; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Safety; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult | 2017 |
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2017 |
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Peptides, Cyclic; Proportional Hazards Models; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2017 |
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pravastatin; Response Evaluation Criteria in Solid Tumors; Small Cell Lung Carcinoma; Survival Rate | 2017 |
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cause of Death; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Sulindac; Survival Rate; Treatment Outcome | 2009 |
Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease"
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Recombinant Proteins; Safety; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase 2 Inhibitors; Disease Progression; Etoposide; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Portugal; Pyrazoles; Quality of Life; Small Cell Lung Carcinoma; Spain; Sulfonamides; Time Factors; Treatment Outcome | 2009 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Rate; Tirapazamine; Triazines | 2009 |
Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2010 |
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fatigue; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Pemetrexed; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2010 |
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Cisplatin; Disease-Free Survival; E-Selectin; Etoposide; Female; Fibroblast Growth Factor 2; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Risk Assessment; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome; United States; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Central nervous system relapse continues to be a therapeutic challenge in extensive disease small-cell lung cancer patients with initial symptomatic brain metastases and good response to chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Secondary Prevention; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2010 |
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2010 |
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; International Agencies; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2010 |
Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
[A prospective randomized study of the radiotherapy volume for limited-stage small cell lung cancer: a preliminary report].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lung Injury; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Tumor Burden | 2010 |
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2010 |
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2011 |
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Etoposide; Female; Germany; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carboplatin; Darbepoetin alfa; Disease-Free Survival; Erythropoietin; Etoposide; Female; Hematinics; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Small Cell Lung Carcinoma | 2011 |
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Transfusion; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia | 2011 |
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2011 |
Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Early Termination of Clinical Trials; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Patient Dropouts; Platinum; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome | 2011 |
Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2012 |
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Thorax | 2012 |
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System; Drug Administration Schedule; Etoposide; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Small Cell Lung Carcinoma | 2012 |
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Protocols; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Small Cell Lung Carcinoma; Topotecan | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
Combination of three cytotoxic agents in small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
[A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Safety; Small Cell Lung Carcinoma | 2013 |
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thalidomide | 2013 |
Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Chromatography, High Pressure Liquid; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma | 2008 |
249 other study(ies) available for etoposide and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Drug Design; Humans; Indoles; Lung Neoplasms; Mice; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2017 |
A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Colchicine; Humans; Lung Neoplasms; Microtubules; Protein Conformation; Small Cell Lung Carcinoma; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2020 |
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
Topics: Adenosine Triphosphatases; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Etoposide; Fatty Acid Synthases; Fatty Acids; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Progression-Free Survival; Prospective Studies; Sequence Analysis, RNA; Small Cell Lung Carcinoma; Survival Analysis; Whole Genome Sequencing | 2021 |
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2022 |
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Italy; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.
Topics: Animals; Cyclic GMP-Dependent Protein Kinases; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplastic Cells, Circulating; Nitric Oxide; Nitric Oxide Synthase Type II; Receptors, Notch; Signal Transduction; Small Cell Lung Carcinoma; Soluble Guanylyl Cyclase | 2021 |
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Etoposide; Humans; Lung Neoplasms; Mice; Oncolytic Virotherapy; Small Cell Lung Carcinoma | 2022 |
Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Carboplatin; Cell Line, Tumor; Cell Proliferation; Etoposide; Female; Humans; Immunoconjugates; Lung Neoplasms; Maytansine; Mice; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Small Cell Lung Carcinoma; Trastuzumab; Tubulin Modulators; Xenograft Model Antitumor Assays | 2022 |
Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Topics: Brain Neoplasms; Etoposide; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Etoposide; Humans; Immunoconjugates; Lung Neoplasms; Peptides; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Small Cell Lung Carcinoma; Topoisomerase Inhibitors | 2022 |
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Indoles; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Quinolines; Small Cell Lung Carcinoma | 2022 |
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Topics: Animals; Cell Death; Enzyme Inhibitors; Etoposide; Histone Demethylases; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lysine; Mice; Platinum; Small Cell Lung Carcinoma; Tumor Microenvironment | 2022 |
A 75-Year-Old Female Smoker with Advanced Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status 2 who Responded to Combination Immunochemotherapy with Atezolizumab, Etoposide, and Carboplatin.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Group Processes; Humans; Immunotherapy; Lung Neoplasms; Small Cell Lung Carcinoma; Smokers | 2022 |
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Platinum; Small Cell Lung Carcinoma | 2022 |
Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Prospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2022 |
Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2022 |
Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Veterans | 2022 |
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2022 |
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2022 |
Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
Thoracic Radiotherapy Effect on the Outcome in Extensive Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Remission Induction; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Concomitant Chemoradiotherapy Using Carboplatin and Etoposide-induced Cutaneous Vasculitis in a Patient with Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Etoposide; Humans; Lung Neoplasms; Skin Diseases, Vascular; Small Cell Lung Carcinoma | 2022 |
Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
The novel role of etoposide in inhibiting the migration and proliferation of small cell lung cancer and breast cancer via targeting Daam1.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Etoposide; Lung Neoplasms; Mice; Mice, Nude; Microfilament Proteins; rho GTP-Binding Proteins; Small Cell Lung Carcinoma; Wnt Proteins | 2023 |
Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Propensity Score; Small Cell Lung Carcinoma | 2023 |
First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Immunotherapy; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
Topics: Etoposide; Humans; Lung Neoplasms; Phenotype; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Topics: Animals; Etoposide; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-myc; Small Cell Lung Carcinoma | 2023 |
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Early Detection of Cancer; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma | 2023 |
Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lung Neoplasms; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Relationship between immune-related adverse events and treatment effectiveness in extensive disease small cell lung cancer.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Etoposide; Humans; Lung Neoplasms; Nivolumab; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2023 |
Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Topics: Aged; Etoposide; Humans; Lung Neoplasms; Middle Aged; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Benmelstobart Ups ES-SCLC Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Platinum; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Topics: B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Retrospective Studies; Small Cell Lung Carcinoma | 2023 |
A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Mutation; ROC Curve; Small Cell Lung Carcinoma | 2019 |
Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Arginase; Cell Line, Tumor; Cell Movement; Cisplatin; Contactin 1; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Gene Knockdown Techniques; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Small Cell Lung Carcinoma | 2019 |
The role of 18F-FDG PET/CT in management of paraneoplastic limbic encephalitis combined with small cell lung cancer: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Limbic Encephalitis; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Small Cell Lung Carcinoma; Treatment Outcome; Whole Body Imaging | 2019 |
Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression.
Topics: Adult; Aged; beta Catenin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Middle Aged; Protein-Tyrosine Kinases; Repressor Proteins; RNA, Long Noncoding; Small Cell Lung Carcinoma | 2020 |
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United Kingdom | 2019 |
Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medicare; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; United States | 2020 |
Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphocytes; Male; Polyethylene Glycols; Prognosis; Prospective Studies; Receptors, Antigen, T-Cell; Recombinant Proteins; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Follow-Up Studies; Hospitalization; Humans; Lung Neoplasms; Male; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2020 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Circulating tumor cell clusters and circulating tumor cell-derived explant models as a tool for treatment response.
Topics: Animals; Antineoplastic Agents; Blood Cells; Disease Progression; Etoposide; Humans; Mice, Nude; Neoplastic Cells, Circulating; Platinum; Small Cell Lung Carcinoma | 2020 |
IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Synergism; Etoposide; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Proteins; Organoplatinum Compounds; Progression-Free Survival; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis | 2020 |
Role of mTOR As an Essential Kinase in SCLC.
Topics: Cisplatin; Etoposide; Humans; Lung Neoplasms; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2020 |
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2021 |
Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Quality of Life; Small Cell Lung Carcinoma; Treatment Outcome | 2021 |
Etoposide and immunotherapy can improve the outcome of severe anti-GABAB R encephalitis presenting with delta brush: A case report.
Topics: Anti-Inflammatory Agents; Autoantibodies; Electroencephalography; Encephalitis; Etoposide; Hashimoto Disease; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Receptors, GABA-B; Small Cell Lung Carcinoma; Topoisomerase II Inhibitors | 2020 |
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC.
Topics: Cranial Irradiation; Etoposide; Humans; Lung Neoplasms; Radium; Small Cell Lung Carcinoma; United States | 2021 |
Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
Topics: Administration, Oral; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Quinolines; Renal Dialysis; Renal Insufficiency; Small Cell Lung Carcinoma; Topoisomerase II Inhibitors; Treatment Outcome | 2020 |
Pulmonary microinvasive small cell carcinoma with an extensive in-situ component identified after photodynamic therapy for 'squamous cell carcinoma in situ': a case report.
Topics: Aged; Antineoplastic Agents; Bronchoscopy; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Male; Photochemotherapy; Small Cell Lung Carcinoma | 2021 |
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer.
Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan | 2020 |
ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Protein-Arginine N-Methyltransferases; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Smad7 Protein; Small Cell Lung Carcinoma; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2021 |
Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Etoposide; Female; Humans; Male; Markov Chains; Neoplasm Staging; Platinum; Progression-Free Survival; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2022 |
Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Topics: Etoposide; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma | 2021 |
Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids.
Topics: Antineoplastic Agents; Cisplatin; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Organ Culture Techniques; Organoids; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2021 |
Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function.
Topics: Aged; Antineoplastic Agents; Disease Progression; Dyspnea; Etoposide; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Neoplasms; Male; Organoplatinum Compounds; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Small Cell Lung Carcinoma; Survival Analysis | 2021 |
Chemotherapy as cause of refractory severe headache in a case of small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Headache; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2021 |
Lysosome Fe
Topics: Cisplatin; Etoposide; Humans; Lung Neoplasms; Lysosomes; Small Cell Lung Carcinoma | 2021 |
Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; China; Etoposide; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Paraneoplastic Syndromes, Nervous System; Small Cell Lung Carcinoma | 2022 |
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Topics: Aged; Antibodies, Monoclonal; Cost-Benefit Analysis; Etoposide; Humans; Lung Neoplasms; Medicare; Platinum; Small Cell Lung Carcinoma; United States | 2021 |
Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
Topics: Aged; Carboplatin; Chemoradiotherapy; Cisplatin; Cranial Irradiation; Early Detection of Cancer; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Male; Neoplasm Staging; Small Cell Lung Carcinoma; Survival Analysis; Survival Rate | 2017 |
Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thoracic Wall; Time Factors | 2017 |
Secondary biopsy of non-oncogenic-driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases.
Topics: Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Consideration of alternative causes of lactic acidosis: Thiamine deficiency in malignancy.
Topics: Acidosis, Lactic; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Confusion; Etoposide; Humans; Male; Psychomotor Agitation; Small Cell Lung Carcinoma; Thiamine; Thiamine Deficiency; Treatment Outcome; Vitamin B Complex | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose Fractionation, Radiation; Esophagitis; Esophagus; Etoposide; Female; Heart; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Prospective Studies; Proton Therapy; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma; Spinal Cord; Treatment Outcome | 2017 |
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Small Molecule Libraries | 2017 |
TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Sirolimus; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2017 |
Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Base Sequence; Beclin-1; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; MicroRNAs; Middle Aged; RNA Interference; RNA, Small Interfering; Sequence Alignment; Small Cell Lung Carcinoma; Up-Regulation | 2017 |
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Carboplatin; Etoposide; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2018 |
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Pleural Effusion, Malignant; Small Cell Lung Carcinoma | 2018 |
Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Transformation, Neoplastic; Clone Cells; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Small Cell Lung Carcinoma | 2018 |
Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Cisplatin; Etoposide; Female; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Retrospective Studies; Small Cell Lung Carcinoma; Thrombocytopenia | 2019 |
Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report.
Topics: Aged; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bronchoscopy; Clarithromycin; Drug Therapy, Combination; Etoposide; Humans; Lung; Lung Neoplasms; Male; Mycobacterium avium; Peptide Fragments; Recombinant Proteins; Rifampin; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Tuberculosis, Avian | 2018 |
Lambert-Eaton myasthenic syndrome developing post-diagnosis of small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carboplatin; Diagnosis, Differential; Disease Progression; Etoposide; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Neoplasm Staging; Neurologic Examination; Prognosis; Small Cell Lung Carcinoma; Terminal Care | 2018 |
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Genotype; Glucuronosyltransferase; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Small Cell Lung Carcinoma | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
[Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Interleukin Receptor Common gamma Subunit; Lung Neoplasms; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Small Cell Lung Carcinoma; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2019 |
[Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA-Directed DNA Polymerase; Etoposide; Genetic Variation; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Regression Analysis; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Survival; Checkpoint Kinase 1; Cisplatin; CRISPR-Associated Protein 9; DNA Damage; Drug Synergism; Etoposide; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Small Cell Lung Carcinoma; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Pyrimidines; Small Cell Lung Carcinoma; Sulfoxides | 2019 |
Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
Topics: Aged; Bridged-Ring Compounds; Cardiovascular Diseases; Etoposide; Female; France; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Prognosis; Small Cell Lung Carcinoma; Survival Analysis; Taxoids | 2019 |
A Comprehensive Preclinical Evaluation of Intravenous Etoposide Lipid Emulsion.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Evaluation, Preclinical; Drug Liberation; Drug Stability; Emulsions; Etoposide; Female; Humans; Injections, Intravenous; Lipids; Lung Neoplasms; Male; Oleic Acids; Rats, Wistar; Small Cell Lung Carcinoma | 2019 |
Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Outcome of treatment in patients with small cell lung cancer in poor performance status.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2019 |
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival.
Topics: Adult; Aged; Biomarkers, Tumor; Blood Platelets; Body Mass Index; Etoposide; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Prognosis; Progression-Free Survival; Retrospective Studies; Serum Albumin, Human; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2013 |
Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma | 2014 |
[Up-regulation of DLL1 may promote the chemotherapeutic sensitivity in small cell lung cancer].
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Calcium-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Etoposide; Green Fluorescent Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Microscopy, Fluorescence; Reverse Transcriptase Polymerase Chain Reaction; Small Cell Lung Carcinoma; Transcription Factor HES-1; Up-Regulation | 2013 |
Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Humans; Lipids; Nanocapsules; Small Cell Lung Carcinoma; Solubility | 2013 |
Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; DNA Damage; Drug Synergism; Etoposide; Female; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Reactive Oxygen Species; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2013 |
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Topics: Adenosine Triphosphatases; Adult; Aged; Antigens, Neoplasm; BRCA1 Protein; Carrier Proteins; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Disease-Free Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Etoposide; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Neoplasm; Humans; Lung Neoplasms; Membrane Proteins; Middle Aged; Multivariate Analysis; Predictive Value of Tests; RNA, Messenger; Small Cell Lung Carcinoma; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Treatment Outcome | 2013 |
[Second-line chemotherapy and its survival analysis of 181 patients with extensive-stage small cell lung cancer in a single institute].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2013 |
[Role of homeobox gene A5 in multidrug resistance of human small cell lung cancer cells].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Homeodomain Proteins; Humans; Immunoblotting; Lung Neoplasms; Plasmids; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection | 2013 |
Does routine clinical practice reproduce the outcome of large prospective trials? The analysis of institutional database on patients with limited-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials as Topic; Cranial Irradiation; Databases, Factual; Dose Fractionation, Radiation; Etoposide; Evidence-Based Medicine; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Practice Patterns, Physicians'; Proportional Hazards Models; Prospective Studies; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2014 |
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Etoposide; Gene Expression; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Piperidines; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Small Cell Lung Carcinoma; Snail Family Transcription Factors; Transcription Factors; Xenograft Model Antitumor Assays | 2014 |
Dosing of carboplatin in a patient with amputated legs: A case report.
Topics: Aged; Amputees; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma | 2014 |
Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiat
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proto-Oncogene Proteins c-bcl-2; Radiopharmaceuticals; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed | 2014 |
Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cisplatin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden | 2014 |
Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Medicare; Neoplasm Staging; Prognosis; Retrospective Studies; SEER Program; Small Cell Lung Carcinoma; Survival Rate; United States | 2013 |
Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Sirolimus; Small Cell Lung Carcinoma; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
The patient with ataxia.
Topics: Acute Disease; Aged; Antineoplastic Agents; Ataxia; Carboplatin; Diagnosis, Differential; Etoposide; Humans; Lung; Lung Neoplasms; Male; Palliative Care; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Etoposide; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neutropenia; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazine; Etoposide; Female; Heterografts; Humans; Immunoglobulin G; Lung Neoplasms; Melanoma, Experimental; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; Small Cell Lung Carcinoma | 2014 |
Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; NF-kappa B; Receptors, Tumor Necrosis Factor; Signal Transduction; Small Cell Lung Carcinoma; TWEAK Receptor | 2014 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2014 |
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cell Line, Tumor; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Receptors, Somatostatin; Small Cell Lung Carcinoma; Translational Research, Biomedical | 2015 |
Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Chromogranins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Organic Anion Transporters; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Synaptophysin; Topotecan; Tumor Cells, Cultured | 2015 |
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Cisplatin; ErbB Receptors; Etoposide; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Retinoblastoma Protein; Sequence Analysis, DNA; Smad4 Protein; Small Cell Lung Carcinoma; Smoking; Tumor Suppressor Protein p53; Young Adult | 2015 |
Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 5; Etoposide; Female; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2014 |
Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Cysteine Endopeptidases; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection | 2015 |
[Role of SALL4 in regulating multi-drug resistance of small cell lung cancer and its clinical significance].
Topics: Antineoplastic Agents; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Small Cell Lung Carcinoma; Transcription Factors | 2014 |
[Influence of interference of WIG-1 on the multi-drug resistance in small cell lung cancer].
Topics: Antineoplastic Agents; Apoptosis; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lung Neoplasms; Nuclear Proteins; RNA-Binding Proteins; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Radiography; Small Cell Lung Carcinoma | 2015 |
Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2015 |
Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Small Cell Lung Carcinoma | 2015 |
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome | 2015 |
Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Transfusion; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hematinics; Hemoglobins; Humans; Incidence; Iron; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Prevalence; Retrospective Studies; Small Cell Lung Carcinoma; Spain; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2015 |
Prognosis of small cell lung cancer patients with diabetes treated with metformin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Diabetes Mellitus, Type 2; Etoposide; Female; Humans; Hypoglycemic Agents; Irinotecan; Lung Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Platinum Compounds; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2015 |
Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Immunoassay; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Small Cell Lung Carcinoma | 2016 |
Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2015 |
Elevated Serum Level of Angiopoietin-2 as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer.
Topics: Angiopoietin-2; Biomarkers, Tumor; Cisplatin; Enzyme-Linked Immunosorbent Assay; Etoposide; Humans; Prognosis; Small Cell Lung Carcinoma; Survival Analysis | 2015 |
Effects of Definitive Chemoradiotherapy on Respiratory Function Tests and Quality of Life Scores During Treatment of Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Forced Expiratory Volume; Humans; Lung; Lung Neoplasms; Middle Aged; Quality of Life; Retrospective Studies; Small Cell Lung Carcinoma; Vital Capacity | 2015 |
[Role and clinical significance of RLIP76 in regulation of multi-drug resistance of small cell lung cancer].
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Cisplatin; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; GTPase-Activating Proteins; Humans; Lung Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Small Cell Lung Carcinoma; Transfection; Up-Regulation | 2015 |
The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Etoposide; Guidelines as Topic; Humans; Japan; Remission Induction; Small Cell Lung Carcinoma | 2015 |
A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Etoposide; Fluorescence; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2016 |
[A Case of Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy with Carboplatin plus Etoposide in a Hemodialysis Patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Dialysis; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma | 2016 |
Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Comorbidity; Decision Support Techniques; Dose Fractionation, Radiation; Dyspnea; Etoposide; Female; Health Status; Health Status Indicators; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2016 |
Prognostic significance of standardised uptake value (SUV
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Retrospective Studies; Serum Albumin; Small Cell Lung Carcinoma | 2017 |
[Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Humans; Hypokinesia; Leukopenia; Lung Neoplasms; Nausea; Neutropenia; Remission Induction; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia; Vomiting | 2016 |
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medicare; Small Cell Lung Carcinoma; Treatment Outcome; United States | 2016 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Topics: Aged; Antineoplastic Agents; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
[Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Etoposide; Genetic Variation; Genotype; Haplotypes; Humans; Lung Neoplasms; Odds Ratio; Polymorphism, Single Nucleotide; Proportional Hazards Models; Rad52 DNA Repair and Recombination Protein; Regression Analysis; Risk; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
Small cell carcinoma of the pyriform sinus successfully treated with concurrent chemo-radiotherapy: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Etoposide; Humans; Hypopharyngeal Neoplasms; Lung Neoplasms; Male; Neoplasms, Second Primary; Pyriform Sinus; Small Cell Lung Carcinoma | 2016 |
Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Treatment Outcome | 2016 |
CXCR4 antagonists suppress small cell lung cancer progression.
Topics: Animals; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cisplatin; Cyclams; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Heterocyclic Compounds; Humans; Lung Neoplasms; Mice; Mice, Knockout; Neoplasm Metastasis; Nuclear Proteins; Peptides; Receptors, CXCR4; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2016 |
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2017 |
Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Drug Carriers; Drug Synergism; Electrophoresis; Erythrocytes; Etoposide; Flow Cytometry; Hemolysis; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kinetics; Lung Neoplasms; Microscopy, Electron, Scanning; Nanotubes, Carbon; Nucleic Acids; Oligonucleotides; Oligonucleotides, Antisense; Polyethylene Glycols; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Small Cell Lung Carcinoma | 2017 |
Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calibration; Cisplatin; Disease Progression; Drug Dosage Calculations; Etoposide; Humans; Lung Neoplasms; Models, Theoretical; Neoplasm Staging; Small Cell Lung Carcinoma; Treatment Outcome; Tumor Burden | 2017 |
Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
Topics: Bevacizumab; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neovascularization, Pathologic; Small Cell Lung Carcinoma | 2017 |
[Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Genetic Variation; Genotype; Glutathione Synthase; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum Compounds; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Risk; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide.
Topics: Adenosine Triphosphatases; Adult; Aged; Apoptosis; ATPases Associated with Diverse Cellular Activities; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Male; Microtubule-Associated Proteins; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Signal Transduction; Small Cell Lung Carcinoma | 2017 |
Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; ROC Curve; Small Cell Lung Carcinoma; Tumor Burden; Vinblastine; Vinorelbine | 2009 |
Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Diabetic Nephropathies; Disease-Free Survival; Etoposide; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Renal Dialysis; Small Cell Lung Carcinoma | 2008 |
Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.
Topics: Annexin A5; Antineoplastic Agents; Benzamides; Cell Survival; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Small Cell Lung Carcinoma | 2008 |
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2008 |
[Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Doxorubicin; Etoposide; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Palliative Care; Piperazines; Pyrimidines; Small Cell Lung Carcinoma; Stomach Neoplasms | 2009 |
Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
Down-regulation of GRP78 is associated with the sensitivity of chemotherapy to VP-16 in small cell lung cancer NCI-H446 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Calcimycin; Cell Cycle; Cell Line, Tumor; Down-Regulation; Egtazic Acid; Endoplasmic Reticulum Chaperone BiP; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Chaperones; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma | 2008 |
Re: 'A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small-cell lung cancer: a randomized trial'.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Research Design; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells.
Topics: Antineoplastic Agents; Caspases; Cell Line, Tumor; Complex Mixtures; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Ganoderma; Humans; Lung Neoplasms; Small Cell Lung Carcinoma | 2009 |
[A case of small cell lung cancer with dermatomyositis that deteriorated with leukocytopenia due to chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dermatomyositis; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Small Cell Lung Carcinoma | 2008 |
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2009 |
Results of surgical treatment for patients with small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Preoperative Care; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Vincristine | 2009 |
The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Disease Progression; Etoposide; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Neoplasm Staging; Plasma; Prognosis; Retrospective Studies; Sex Factors; Small Cell Lung Carcinoma; Sodium; Survival Analysis | 2010 |
A newly developed lung nodule during chemotherapy for small cell lung cancer. Chronic necrotising pulmonary aspergillosis.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronic Disease; Etoposide; Humans; Lung Neoplasms; Male; Pulmonary Aspergillosis; Pyrimidines; Small Cell Lung Carcinoma; Triazoles; Voriconazole | 2009 |
Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Radiotherapy, Adjuvant; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vincristine | 2009 |
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Irradiation; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo.
Topics: Animals; Cell Line, Tumor; Decanoic Acids; Dicarboxylic Acids; Disease Models, Animal; Drug Delivery Systems; Etoposide; Female; Humans; Kaplan-Meier Estimate; Kinetics; Lung Neoplasms; Mice; Microscopy, Electron, Scanning; Polyethylene Glycols; Small Cell Lung Carcinoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Platinum; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma | 2009 |
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Humans; Ifosfamide; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis | 2010 |
Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Cladribine; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Mucous Membrane; Neoplasms, Second Primary; Rituximab; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2009 |
Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etoposide; Humans; Incidence; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Thalidomide; Thromboembolism | 2009 |
[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Carboplatin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
The combination of Young's syndrome and small cell lung cancer-A spiky connection?
Topics: Antineoplastic Agents; Azoospermia; Carboplatin; Etoposide; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Radiography; Sinusitis; Small Cell Lung Carcinoma; Syndrome | 2010 |
[Successful treatment of small cell lung cancer with secondary immune thrombocytopenic purpura].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Purpura, Thrombocytopenic; Small Cell Lung Carcinoma | 2009 |
Iatrogenic tracheoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Fatal Outcome; Female; Humans; Iatrogenic Disease; Lung Neoplasms; Middle Aged; Radiotherapy; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Tracheoesophageal Fistula | 2009 |
[Small cell lung cancer with Sézary syndrome].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Sezary Syndrome; Small Cell Lung Carcinoma | 2009 |
Chemotherapy: continued lack of progress in SCLC.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Etoposide; Glutamates; Guanine; Humans; Neoplasm Staging; Pemetrexed; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Etoposide; Female; Granulocyte Precursor Cells; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Topics: Antineoplastic Agents; Cell Cycle; Cisplatin; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Humans; Lung Neoplasms; Microarray Analysis; MicroRNAs; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Small Cell Lung Carcinoma; Transfection; Tumor Cells, Cultured | 2010 |
Sequential fluctuating paraneoplastic ocular flutter-opsoclonus-myoclonus syndrome and Lambert-Eaton myasthenic syndrome in small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Opsoclonus-Myoclonus Syndrome; Small Cell Lung Carcinoma | 2011 |
Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Caspase 8; Cell Line, Tumor; Doxorubicin; Enzyme Activation; Etoposide; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Small Cell Lung Carcinoma; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Etoposide; Female; Gene Expression; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, SCID; Microarray Analysis; Neoplasm Transplantation; Small Cell Lung Carcinoma; Transplantation, Heterologous; Valproic Acid | 2010 |
Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer.
Topics: Carboplatin; Cisplatin; Etoposide; Female; Genes; Genome; Humans; Inuit; Lung Neoplasms; Male; Middle Aged; Nerve Tissue Proteins; Platinum; Polymorphism, Single Nucleotide; R-SNARE Proteins; Small Cell Lung Carcinoma | 2010 |
Solitary brain metastasis of an occult and stable small-cell lung cancer in a schizophrenic patient: a 3-year control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Brain Neoplasms; Carboplatin; Clozapine; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Radiotherapy; Schizophrenia; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2010 |
Successful chemotherapy for small-cell lung cancer in an elderly patient undergoing continuous ambulatory peritoneal dialysis.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Peritoneal Dialysis, Continuous Ambulatory; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
[Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2010 |
Neutropenic enterocolitis during first-line chemotherapy with carboplatin and etoposide in small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Enterocolitis, Neutropenic; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Radiography; Small Cell Lung Carcinoma | 2011 |
Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Treatment Outcome | 2010 |
Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; DNA-Binding Proteins; Etoposide; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; HEK293 Cells; HSP72 Heat-Shock Proteins; Humans; Immunoblotting; Lung Neoplasms; Membrane Potential, Mitochondrial; Microscopy, Confocal; Nuclear Proteins; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; Small Cell Lung Carcinoma; Tumor Protein p73; Tumor Suppressor Proteins | 2011 |
Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Differentiation; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Epithelial Cells; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Microscopy, Electron, Transmission; Muscle, Skeletal; Myofibroblasts; Neoplasm Staging; Neurosecretory Systems; Pneumonectomy; Small Cell Lung Carcinoma; Smoking | 2011 |
The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Idiopathic Interstitial Pneumonias; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2011 |
Reversible posterior leukoencephalopathy induced by carboplatin and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Prognosis; Small Cell Lung Carcinoma | 2012 |
Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2011 |
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Chemical Analysis; Calibration; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials, Phase I as Topic; Drug Synergism; Etoposide; Humans; Indoles; Lung Neoplasms; Prognosis; Pyrroles; Small Cell Lung Carcinoma | 2011 |
[Thoracic radiation therapy improves the prognosis for patients with extensive stage small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Humans; Lung Neoplasms; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2011 |
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Two novel determinants of etoposide resistance in small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA Polymerase beta; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carcinoma; Transcription Factors; Zebrafish Proteins | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.
Topics: Age Factors; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Heparin; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2011 |
MicroRNA expression and clinical outcome of small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Screening Assays, Antitumor; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2011 |
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Depsipeptides; DNA Breaks, Double-Stranded; Drug Synergism; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Models, Theoretical; Phosphorylation; Small Cell Lung Carcinoma; Sulfonamides; Time Factors | 2011 |
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Clinical Trials, Phase III as Topic; Collagen Type XVIII; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Etoposide; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Methylenetetrahydrofolate Reductase (NADPH2); Pemetrexed; Peptide Synthases; Phosphoribosylglycinamide Formyltransferase; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Reduced Folate Carrier Protein; Small Cell Lung Carcinoma; Thymidylate Synthase | 2012 |
Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Etoposide; Female; Follow-Up Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Topoisomerases, Type I; DNA-Binding Proteins; Doxorubicin; Endonucleases; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Transcription, Genetic; Vincristine | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Etoposide; Female; Gene Frequency; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Small Cell Lung Carcinoma; Vincristine | 2012 |
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide.
Topics: ACTH Syndrome, Ectopic; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Metyrapone; Middle Aged; Small Cell Lung Carcinoma | 2011 |
[Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myelopoiesis; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2012 |
An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Time Factors | 2012 |
Is diabetes mellitus a prognostic factor for survival in patients with small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diabetes Complications; Etoposide; Female; Hemoglobins; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Serum Albumin; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed | 2012 |
Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Array Analysis; Proteomics; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Support Vector Machine; Treatment Outcome | 2012 |
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Etoposide; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Pemetrexed; Prognosis; Proportional Hazards Models; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma | 2012 |
Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Fluorine Compounds; Glycosides; Humans; Male; Microsomes, Liver; Monosaccharides; Podophyllotoxin; Rats; Rats, Sprague-Dawley; Small Cell Lung Carcinoma; Topoisomerase II Inhibitors | 2012 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
Treatment update in small-cell lung cancer: from limited to extensive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan | 2012 |
Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Vinblastine | 2012 |
Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiotherapy Dosage; Severity of Illness Index; Small Cell Lung Carcinoma; Tumor Burden | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome | 2015 |
[Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Etoposide; Female; France; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2006 |